GlassScriptPhysician profile
Mark J Jobman
NPI 1134137706
$3,144.95
in general payments reported to CMS, 2019-2025
31 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $378 · 2021: $723 · 2022: $553 · 2023: $365 · 2024: $374 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $976.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $488.13 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $448.97 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $238.35 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $191.37 | 2019-2023 | |
| Abbvie INC. | $152.93 | 2019-2025 | |
| Lilly USA, LLC | $151.59 | 2020-2024 | Mounjaro, Jardiance |
| Astellas Pharma US INC | $144.41 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.22 | 2019-2022 | |
| Glaxosmithkline, LLC. | $134.19 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $134.00 | 2020-2023 | Gvoke Hypopen |
| Amgen INC. | $130.38 | 2019-2024 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $119.96 | 2021-2024 | |
| Exact Sciences Corporation | $88.02 | 2023-2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $86.34 | 2019-2024 | Watchman Flx |
| Merck Sharp & Dohme LLC | $81.96 | 2022-2024 | Capvaxive, Gardasil, Gardasil 9 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $48.94 | 2019-2021 | |
| Dexcom, INC. | $39.52 | 2021-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $37.85 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $33.01 | 2022-2023 | Leqvio |
| Philips North America LLC | $31.75 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.90 | 2021-2023 | Xifaxan |
| Medtronic, INC. | $29.63 | 2025 | Symplicity G3 |
| Allergan, INC. | $29.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.42 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.08 | 2022 | |
| Scpharmaceuticals INC. | $16.95 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.76 | 2021 | |
| Eisai INC. | $14.07 | 2021 | |
| Mylan Specialty L.P. | $14.03 | 2024 | Yupelri |
| Abbott Laboratories | $13.80 | 2024 | Eterna |
| Teva Pharmaceuticals USA, INC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jobman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.